^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PML-JAK1 fusion

    i
    Other names: PML, Promyelocytic Leukemia, Tripartite Motif-Containing Protein 19, Promyelocytic Leukemia Protein, RING Finger Protein 71, Protein PML, PP8675, TRIM19, RNF71, MYL, Promyelocytic Leukemia, Inducer Of, Probable Transcription Factor PML, Tripartite Motif Protein TRIM19, PML/RARA Fusion, Janus Kinase 1, Tyrosine-Protein Kinase JAK1, JAK1B, JAK1A, JAK-1, JTK3
    Entrez ID:
    3716; 5371
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    over3years
    [VIRTUAL] Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification. (ASCO 2021)
    Several rare and novel fusions were identified; a sarcoma with TPM4-NTRK3 fusion responded to larotrectinib, while a sarcoma with PML-JAK1 fusion did not respond to ruxolitinib, and a sarcoma with IL7R-BCL2 fusion progressed on venetoclax . NGS profiling led to a targeted therapy with a clinical benefit rate of 12% in this cohort . NGS profiling led to a change in diagnosis in 5% of this cohort . Multi-institutional collaborations to track outcomes of matched therapy would help determine the utility of therapies in rare cancers and unusual alterations.
    Clinical • Next-generation sequencing • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TPM4 (Tropomyosin 4)
    |
    TMB-H • NTRK3 fusion • MET amplification • IL7R-BCL2 fusion • PML-JAK1 fusion • TPM4-NTRK3 fusion • BCL2 fusion
    |
    Venclexta (venetoclax) • Xalkori (crizotinib) • Vitrakvi (larotrectinib) • Jakafi (ruxolitinib)